{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T15:19:18Z","timestamp":1770477558739,"version":"3.49.0"},"reference-count":7,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2006,3,10]],"date-time":"2006-03-10T00:00:00Z","timestamp":1141948800000},"content-version":"vor","delay-in-days":6399,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biopharm &amp; Drug Disp"],"published-print":{"date-parts":[[1988,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In a randomized crossover study, twelve patients presenting a generalized anxiety disorder received either a 1 mg oral tablet or a 1 mg sublingual tablet of lorazepam three times daily for 7 days. After a 7\u2010day washout period, each patient received a 7\u2010day treatment with the other tablet form. Treatments were administered in a double\u2010blind manner using placebos of both the oral and sublingual tablets. Psychiatric evaluations were carried out before and following each of the three periods. Blood samples were drawn at intervals for 48 h following the last dose of each treatment. The plasma concentrations of lorazepam were measured by gas chromatography using an electron\u2010capture detector. Both the oral and sublingual lorazepam produced a significant anxiolytic effect; there was no statistically significant difference between the therapeutic effectiveness of the two forms of lorazepam. The main pharmacokinetic parameters for the oral and sublingual tablets were, respectively: elimination half\u2010life 15.6h and 11.7h; maximal concentration 40.8ngml<jats:sup>\u22121<\/jats:sup> and 42.2ngml<jats:sup>\u22121<\/jats:sup>; time to reach maximal concentration l.2h and 1.4h; corrected area under the curve 310.6ng hml<jats:sup>\u22121<\/jats:sup> and 313.6ng hml<jats:sup>\u22121<\/jats:sup>. There was no statistically significant difference between the oral and sublingual tablets for any of the pharmacokinetic parameters measured.<\/jats:p>","DOI":"10.1002\/bod.2510090504","type":"journal-article","created":{"date-parts":[[2006,10,14]],"date-time":"2006-10-14T11:31:24Z","timestamp":1160825484000},"page":"457-464","source":"Crossref","is-referenced-by-count":14,"title":["Placebo\u2010controlled comparative study of the anxiolytic activity and of the pharmacokinetics of oral and sublingual lorazepam in generalized anxiety"],"prefix":"10.1002","volume":"9","author":[{"given":"J.","family":"Sp\u00e9nard","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Caill\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"V\u00c9Zina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Larivi\u00e8re","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Trudel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Ouellette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"De Montigny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,3,10]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt1976203329"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600680119"},{"key":"e_1_2_1_4_2","first-page":"375","volume-title":"Advances in Neurotoxicology","author":"Caill\u00e9 G.","year":"1980"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/bdd.2510040106"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1983.203"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1982.27"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pa.11.040171.000421"}],"container-title":["Biopharmaceutics &amp; Drug Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fbod.2510090504","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bod.2510090504","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,22]],"date-time":"2023-10-22T06:07:59Z","timestamp":1697954879000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/bod.2510090504"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1988,9]]},"references-count":7,"journal-issue":{"issue":"5","published-print":{"date-parts":[[1988,9]]}},"alternative-id":["10.1002\/bod.2510090504"],"URL":"https:\/\/doi.org\/10.1002\/bod.2510090504","archive":["Portico"],"relation":{},"ISSN":["0142-2782","1099-081X"],"issn-type":[{"value":"0142-2782","type":"print"},{"value":"1099-081X","type":"electronic"}],"subject":[],"published":{"date-parts":[[1988,9]]}}}